Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
The Pfizer Inc. (NYSE: PFE) news page on Stock Titan aggregates company announcements, clinical data readouts, financial updates and legal developments for one of the world’s major biopharmaceutical manufacturers. Pfizer’s news flow reflects its role in pharmaceutical preparation manufacturing, with frequent updates on prescription medicines, vaccines and late‑stage clinical programs.
Investors and observers can find detailed coverage of oncology trial results, such as Phase 3 data for BRAFTOVI (encorafenib) combinations in BRAF V600E‑mutant metastatic colorectal cancer, PADCEV (enfortumab vedotin) plus pembrolizumab in muscle‑invasive bladder cancer, and TUKYSA (tucatinib) in HER2‑positive metastatic breast cancer. These releases typically report on endpoints like objective response rate, progression‑free survival, event‑free survival and overall survival, along with safety profiles and plans for regulatory discussions.
Pfizer news also includes corporate and financial communications, such as earnings webcasts, performance reports, forward‑year revenue and adjusted EPS guidance, and dividend declarations. Recent releases describe full‑year revenue guidance ranges, expected contributions from COVID‑19 products, the impact of loss of exclusivity for certain medicines, and ongoing cost realignment efforts. Dividend announcements highlight Pfizer’s long record of consecutive quarterly cash dividends.
Another important category is business development and pipeline expansion. News items cover transactions like the acquisition of Metsera, which adds GLP‑1‑based obesity candidates, and an exclusive global collaboration and license agreement with YaoPharma for the small‑molecule GLP‑1 receptor agonist YP05002. These updates explain how Pfizer is building its cardiometabolic and obesity portfolio.
Regulatory, safety and legal topics also appear in the news stream, including multidistrict litigation related to Depo‑Provera and FDA label changes adding brain tumor warnings. By following this page, readers can monitor how scientific, financial and legal events shape Pfizer’s outlook and product portfolio over time.
PROTAC market (coverage: 7MM) is forecast to grow sharply through 2034 as targeted protein degradation advances across oncology and other indications. Key pipeline assets include vepdegestrant, luxdegalutamide, ASP3082, and DT2216. The report cites ~90 protein-degradation leads, ~20% in clinical development, and PROTACs representing >30% of the protein degradation pipeline. Strategic partnerships include Arvinas collaborations with Pfizer and Novartis, and a Novartis up-front payment of USD 150 million for ARV-766 rights. Notable trial data: Phase III VERITAC-2 met its ESR1m primary endpoint but not the ITT population.
Pfizer (NYSE: PFE) announced the FDA has accepted and granted Priority Review for the supplemental BLA for HYMPAVZI (marstacimab) to expand use to patients ≥6 years with hemophilia A or B with inhibitors and children 6–11 years without inhibitors.
The FDA set a PDUFA action date in Q2 2026 and previously granted Breakthrough Therapy for prophylaxis in pediatric hemophilia B. Submissions rely on Phase 3 BASIS and BASIS KIDS trial data.
Pfizer (NYSE: PFE) launched a cost-savings program on TrumpRx on February 6, 2026, offering discounts on more than 30 branded medicines across women’s health, migraine, arthritis, rare disease and more. The program offers savings up to 85% and averages 50% off list prices for many primary care and select specialty treatments.
Pfizer says the initiative, part of a voluntary Most Favored Nation agreement with the U.S. government, aims to make medicines more affordable for millions—affecting conditions impacting over 100 million patients—and includes a partnership with GoodRx and expansion of PfizerForAll.
Pfizer (NYSE: PFE) reported full-year 2025 revenues of $62.6B, reported diluted EPS of $1.36 and adjusted diluted EPS of $3.22. Fourth-quarter 2025 revenues were $17.6B with adjusted EPS of $0.66. The company reaffirmed full-year 2026 guidance: revenues $59.5–$62.5B and adjusted EPS $2.80–$3.00, expecting ~$5B COVID product revenue and ~20 key pivotal trial starts in 2026.
Notable items include $4.4B intangible-asset impairments in Q4 2025, significant R&D and BD investments, $9.8B dividends returned, and no share repurchases expected in 2026 under current guidance.
Pfizer (NYSE: PFE) reported positive topline Phase 2b VESPER-3 results for PF’3944, an ultra-long-acting injectable GLP-1 RA, showing up to 12.3% placebo-adjusted mean weight loss at week 28 with a monthly maintenance regimen after weekly titration. The primary endpoint was met (P<0.001) across four dose arms.
PF’3944 maintained a tolerable safety profile through week 28; Pfizer plans >20 obesity trials in 2026, including 10 Phase 3 studies for PF’3944 and a planned higher 9.6 mg monthly dose in Phase 3.
Pfizer (NYSE: PFE) reported Cohort 3 results from the BREAKWATER trial evaluating BRAFTOVI (encorafenib) plus cetuximab and FOLFIRI in previously untreated BRAF V600E-mutant metastatic colorectal cancer. The regimen improved confirmed objective response rate to 64.4% versus 39.2% for FOLFIRI with or without bevacizumab (odds ratio 2.76, p=0.001). Estimated median duration of response was not estimable for the investigational arm; 57.4% of responders on the investigational arm had responses ≥6 months. Overall survival was analyzed descriptively (HR 0.49, 95% CI 0.24–1.03; ~10-month follow-up). No new safety signals identified; 8.5% discontinued BRAFTOVI for adverse reactions. Trial completion estimated 2027.
Summary not available.
Pfizer (NYSE: PFE) will webcast a discussion with Chairman and CEO Albert Bourla at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 9:45 a.m. PST. Registration and access details are available at www.pfizer.com/investors beginning January 5, 2026. A transcript and replay will be posted within 24 hours and remain accessible for at least 90 days.
The webcast may include forward-looking statements about financial performance, pipeline, and strategy; risk disclosures are referenced to Pfizer’s SEC reports.
Pfizer (NYSE: PFE) invites investors and the public to a webcasted conference call with analysts at 10:00 a.m. EST on Tuesday, February 3, 2026 to discuss its Fourth Quarter and Full Year 2025 Performance Report, which will be issued that morning. Registration and webcast access instructions are available at www.pfizer.com/investors. Dial-in numbers: 800-456-4352 (U.S./Canada) or 785-424-1086 (international) using passcode 10856. A transcript and replay will be posted on the investor website within 24 hours and will be accessible for at least 90 days. Contact: IR@Pfizer.com.
Pfizer (NYSE: PFE) and Astellas announced positive topline results from an interim analysis of the Phase 3 EV-304 (KEYNOTE-B15) trial on Dec. 17, 2025.
The trial evaluated PADCEV (enfortumab vedotin) plus Keytruda (pembrolizumab) as neoadjuvant and adjuvant therapy versus standard cisplatin-based neoadjuvant chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC). The study met its primary endpoint with clinically meaningful and statistically significant improvements in event-free survival (EFS) and also showed a statistically significant improvement in overall survival (OS) (key secondary) and in pathologic complete response (pCR). Safety was consistent with the known profile. Results will be presented at a medical meeting and discussed with global health authorities for potential regulatory filings.
FAQ
What is the current stock price of Pfizer (PFE)?
What is the market cap of Pfizer (PFE)?
